A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)

被引：2
|
作者：
Andre, F. [1 ]
Kaufman, B. [2 ]
Juric, D. [3 ]
Ciruelos, E. [4 ]
Iwata, H. [5 ]
Mayer, I. A. [6 ]
Conte, P. [7 ]
Rugo, H. S. [8 ]
Loibl, S. [9 ]
Rubovszky, G. [10 ,11 ]
Tesch, H. [12 ]
Inoue, K. [13 ]
Lu, Y-S. [14 ]
Ryvo, L. [15 ]
Longin, A-S. [16 ]
Mills, D. [16 ,17 ]
Wilke, C. [17 ]
Germa, C. [18 ]
Campone, M. [19 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France
[2] Chaim Sheba Med Ctr, Breast Canc Unit, Ramat Gan, Israel
[3] Massachusetts Gen Hosp, Termeer Ctr Targeted Therapies, Boston, MA 02114 USA
[4] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[5] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[6] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[7] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy
[8] Univ Calif San Francisco, Ctr Comprehens Canc, Med Hematol Oncol, San Francisco, CA 94143 USA
[9] German Breast Grp, Med & Res, Neu Isenburg, Germany
[10] Natl Inst Oncol, Internal Med Oncol Div B, Budapest, Hungary
[11] Natl Inst Oncol, Dept Clin Pharmacol, Budapest, Hungary
[12] Ctr Hamatol & Onkol Bethanien, Dept Oncol, Frankfurt, Germany
[13] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Tel Aviv Sourasky Med Ctr Ichilov, Div Oncol, Tel Aviv, Israel
[16] Novartis Pharma SAS, Paris, France
[17] Novartis Pharma AG, Basel, Switzerland
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Ctr Rene Gauducheau, Med Oncol, Inst Cancerol Ouest Site, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
    Kornblum, Noah
    Zhao, Fengmin
    Manola, Judith
    Klein, Paula
    Ramaswamy, Bhuvaneswari
    Brufsky, Adam
    Stella, Phillip J.
    Burnette, Brian
    Telli, Melinda
    Makower, Della F.
    Cheema, Puneet
    Truica, Cristina I.
    Wolff, Antonio C.
    Soori, Gamini S.
    Haley, Barbara
    Wassenaar, Timothy R.
    Goldstein, Lori J.
    Miller, Kathy D.
    Sparano, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1556 - +
  • [32] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
    Yap, Y. S.
    Tseng, L-M.
    Blackwell, K. L.
    Cameron, D.
    Foo, S.
    Sriuranpong, V.
    Huang, C-S.
    Chao, T-Y.
    Kim, T-Y.
    Chen, S-C.
    Jung, K. H.
    Lee, K. S.
    Sohn, J-H.
    Kim, J. H.
    Hou, M-F.
    Han, Y.
    Souami, F.
    Dhuria, S.
    Miller, M.
    Verma, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
    Royce, Melanie
    Bachelot, Thomas
    Villanueva, Cristian
    Ozguroglu, Mustafa
    Azevedo, Sergio J.
    Cruz, Felipe Melo
    Debled, Marc
    Hegg, Roberto
    Toyama, Tatsuya
    Falkson, Carla
    Jeong, Joon
    Srimuninnimit, Vichien
    Gradishar, William J.
    Arce, Christina
    Ridolfi, Antonia
    Lin, Chinjune
    Cardoso, Fatima
    JAMA ONCOLOGY, 2018, 4 (07) : 977 - 984
  • [35] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De Laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    El-Hashimy, Mona
    Sellami, Dalila
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
  • [36] ADVERSE EVENT MANAGEMENT DURING TREATMENT WITH ALPELISIB FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Colella, Sarah
    Lacouture, Mario
    Farooki, Azeez
    Juric, Dejan
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [37] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Razeq, Hikmat Abdel
    Cottu, Paul
    Ring, Alistair
    De laurentiis, Michelino
    Lu, Janice
    Azim, Hamdy
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
  • [39] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla C.
    Sledge, George W., Jr.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [40] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
    Sawaki, Masataka
    Muramatsu, Yasuaki
    Togo, Kanae
    Iwata, Hiroji
    CANCER RESEARCH, 2023, 83 (05)
12345